Search results for "Colorectal cancer"
Spotlight on newer methods of CRC screening
Recent analyses compared a multitarget stool DNA test for colorectal cancer (CRC) with fecal immunochemical testing (FIT), assessed the cost-effectiveness of new cell-free blood DNA tests for CRC, and looked at a FIT-based screening strategy for lower-income countries.
https://gastroenterology.acponline.org/archives/2024/11/22/5.htm
22 Nov 2024
Aspirin associated with colorectal cancer risk reduction in those with less healthy lifestyles
The least healthy patients had a 1.28% 10-year absolute risk reduction in colorectal cancer with aspirin use compared to only 0.11% among the healthiest patients who took aspirin, according to retrospective data from nurses and health professionals.
https://gastroenterology.acponline.org/archives/2024/08/23/6.htm
23 Aug 2024
Spotlight on colorectal cancer screening intervals
Patients with a complete, negative colonoscopy had reduced risk of colorectal cancer for more than 15 years, one study found, while another found that early-onset colorectal cancer doesn't require more frequent follow-up surveillance than average-onset cases.
https://gastroenterology.acponline.org/archives/2024/05/24/5.htm
24 May 2024
Blood test for colorectal cancer screening approved
The test can be used to screen for colorectal cancer in average-risk individuals who are 45 years of age or older.
https://gastroenterology.acponline.org/archives/2024/08/23/8.htm
23 Aug 2024
A next-generation mt-sDNA test had 94% sensitivity for colorectal cancer and 91% specificity for advanced neoplasia
An ACP Journal Club commentary questioned whether multitarget stool DNA (mt-sDNA) is better than fecal immunochemical testing (FIT) or outperformed FIT because of a lower threshold for colonoscopy referral, recommending that the tests be compared at the same referral rate.
https://gastroenterology.acponline.org/archives/2024/09/27/8.htm
27 Sep 2024
In persons aged ≥45 y, the mt-sRNA test had 94% sensitivity for colorectal cancer and 46% for advanced adenomas
The results of the industry-funded study support the use of the multitarget stool RNA (mt-sRNA) test for screening, but better adherence will be needed, and it is unclear whether the new test offers any advantages over current stool DNA testing, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2024/02/23/6.htm
23 Feb 2024
FIT test completion, yield similar among patients 45 to 49 years and 50-year-olds
In a study of patients completing their first fecal immunochemical test (FIT), those ages 45 to 49 years had a lower adenoma detection rate but a similar rate of colorectal cancer as patients who were 50 years of age when they first underwent screening.
https://gastroenterology.acponline.org/archives/2024/10/25/6.htm
25 Oct 2024
Flexible sigmoidoscopy associated with long-term reduction in colorectal cancer incidence, mortality
Colorectal cancer incidence and mortality were reduced by about 20% in patients who were randomized to receive once-only flexible sigmoidoscopy screening between the ages of 55 to 64 years instead of usual care.
https://gastroenterology.acponline.org/archives/2021/11/19/6.htm
19 Nov 2021
AI-assisted colonoscopy does not improve detection of advanced neoplasias
While colonoscopies with artificial intelligence (AI) assistance yielded more adenomas compared with conventional colonoscopy, rates of advanced neoplasias per colonoscopy did not differ, a systematic review and meta-analysis found.
https://gastroenterology.acponline.org/archives/2024/10/25/2.htm
25 Oct 2024
ACG lowers suggested age for colorectal cancer screening in updated guidelines
The American College of Gastroenterology (ACG) continues to recommend colorectal cancer screening in average-risk adults ages 50 to 75 years but now also suggests it in those ages 45 to 49 years.
https://gastroenterology.acponline.org/archives/2021/03/26/1.htm
26 Mar 2021